Oruka Therapeutics, Inc. (NASDAQ: ORKA) is a clinical-stage biotechnology company developing novel biologics for chronic skin diseases, and its news flow reflects the progress of a focused dermatology pipeline. Company press releases highlight advances for its lead monoclonal antibodies ORKA-001 and ORKA-002, both engineered to target key immunology pathways in plaque psoriasis and related conditions while enabling infrequent dosing.
News updates frequently cover clinical milestones such as Phase 1 interim data, initiation and enrollment of Phase 2 trials, and detailed designs of the EVERLAST-A and EVERLAST-B studies of ORKA-001 in moderate-to-severe plaque psoriasis. Oruka also reports on the first-in-human trial of ORKA-002, including pharmacokinetic and pharmacodynamic findings that support potential twice-yearly dosing in psoriasis and quarterly dosing in hidradenitis suppurativa.
In addition to pipeline developments, Oruka’s news includes quarterly financial results, corporate updates, and capital-raising activities, such as a private placement financing described in company communications. Governance and leadership items, including board appointments and executive promotions, are disclosed through both press releases and Form 8-K filings. The company also announces participation in major healthcare and investor conferences, where it presents clinical data and corporate overviews.
Investors and observers following ORKA news can expect coverage of clinical trial data readouts, regulatory milestones such as IND clearance, financing transactions, and changes in leadership or board composition. This page aggregates those updates so readers can monitor how Oruka’s psoriatic disease programs and broader antibody portfolio evolve over time.
Oruka Therapeutics, Inc. (Nasdaq: ORKA) has completed its merger with ARCA biopharma and a $275 million private placement. The company, focused on developing novel biologics for chronic skin diseases, begins trading on Nasdaq on September 3, 2024. Samarth Kulkarni, PhD, has been appointed as Chairman of Oruka's Board of Directors.
Oruka's pipeline includes two lead programs: ORKA-001, a subcutaneous IL-23p19 inhibitor potentially dosed once or twice yearly, and ORKA-002, a subcutaneous IL-17A/F inhibitor. Both aim to offer improved dosing regimens and greater clinical activity for psoriasis and related conditions. The company plans to advance these programs into clinical trials, with initial pharmacokinetic data for ORKA-001 expected next year.